Clinical trial NCT03146676: The Ohio State University Dermatology Biorepository
Official title: The Ohio State University Dermatology Biorepository
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hidradenitis Suppurativa
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2017-05-10
Enrollment: 175
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Any person that meets the inclusion/exclusion criteria

Brief summary: This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.

Detailed description: A variety of molecular techniques can be used to investigate diseases by analyzing protein, DNA, and RNA. Flow cytometry, Polymerase chain reaction (PCR), histology and immunohistochemistry are assays which can identify specific cell populations and provide valuable information regarding the pathologic characteristics of those populations. Flow cytometry analyzes the surface markers of cells. Histology and immunohistochemistry further characterize surface and cellular molecules and aid in the diagnosis of certain skin diseases. Gene expression profiling allows investigators to examine the genes detectable to determine the function of the cells involved, and PCR techniques are useful for the diagnosis of certain conditions and for DNA analysis.

By procuring blood, skin tissue, and swab samples from patients with and without neoplastic and inflammatory skin disorders at the time of their appointments, the hypothesize that future translational research can be conducted on such specimens using the aforementioned techniques to further understand disease mechanisms in cutaneous disorders, and to potentially discover defective function and genetic mutations within cells from patients with neoplastic and inflammatory skin disorders. By establishing a tissue bank, we aim to lay the foundation for future work that will improve our understanding of the biology and natural history of neoplastic and inflammatory cutaneous diseases.

Eligibility criteria: Inclusion Criteria:

* Seen by an Ohio State University (OSU) Dermatology provider on the main University Hospital campus, including the James Cancer Hospital, OSU Dermatology East, OSU Dermatology at the Ohio State Eye and Ear Institute, Martha Morehouse Medical Pavilion, and OSU Dermatology at Upper Arlington after the date of approval of this protocol
* Ability to provide informed consent, or parent or legal guardian capable of providing consent for child or mentally handicapped individuals
* Willingness to participate in a research study.

Exclusion Criteria:

* Inability to provide informed consent

Primary outcomes:
measure: Source of clinical specimens for the future study of neoplastic and inflammatory skin disorders
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: OSU Dermatology West
state: Ohio
Study officials:
affiliation: Dermatologist
name: Benjamin Kaffenberger, MD
role: PRINCIPAL_INVESTIGATOR
References: